|
Volumn 458, Issue , 1999, Pages 11-21
|
Lamivudine therapy of chronic hepatitis B
a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ACICLOVIR;
ADEFOVIR;
ALANINE AMINOTRANSFERASE;
ALPHA INTERFERON;
ASPARTATE AMINOTRANSFERASE;
DIDANOSINE;
FAMCICLOVIR;
FIALURIDINE;
GANCICLOVIR;
HEPATITIS B SURFACE ANTIGEN;
HEPATITIS B(E) ANTIGEN;
LAMIVUDINE;
LOBUCAVIR;
NUCLEOSIDE DERIVATIVE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
VIDARABINE;
VIRUS DNA;
ZALCITABINE;
ZIDOVUDINE;
ANEMIA;
ANTIVIRAL ACTIVITY;
CANCER PREVENTION;
CANCER RISK;
CHRONIC HEPATITIS;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOSE TIME EFFECT RELATION;
DRUG EFFICACY;
DRUG TOLERABILITY;
HEPATITIS B;
HEPATITIS B VIRUS;
HUMAN;
LACTIC ACIDOSIS;
LIVER CARCINOMA;
LIVER TRANSPLANTATION;
MULTIPLE ORGAN FAILURE;
NEUROTOXICITY;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
RECURRENT DISEASE;
SEROCONVERSION;
VIRUS MUTATION;
DNA VIRUSES;
HEPATITIS B VIRUS;
|
EID: 0033281793
PISSN: 00652598
EISSN: None
Source Type: Book Series
DOI: 10.1007/978-1-4615-4743-3_2 Document Type: Conference Paper |
Times cited : (4)
|
References (40)
|